Floatz logo

Cediranib

BRAF Gene Mutation

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the BRAF Gene Mutation cohort.

Asset / SponsorPhaseRating
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE
TriHealth Inc.
Phase 2B
gsk1120212
Rina Plattner
Phase 2B
Epirubicin
University of Southern California
Phase 2B
Pembrolizumab
University of Southern California
Phase 2B
Cyclophosphamide
University of Southern California
Phase 2B

View all 22 →

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →